DBPR 108

Drug Profile

DBPR 108

Alternative Names: DBPR108; Diabetes therapeutic - ScinoPharm/National Health Research Institutes

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Health Research Institutes; ScinoPharm
  • Developer National Health Research Institutes
  • Class Antihyperglycaemics
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in Taiwan (PO, Capsule)
  • 31 Jan 2015 National Health Research Institute completes a phase I trial in healthy male volunteers in Taiwan (NCT02163278)
  • 01 Jun 2014 National Health Research Institutes initiates enrolment in a phase I trial for Type-2 diabetes mellitus in Taiwan (NCT02163278)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top